Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Other Non-Current Assets for 7 consecutive years, with $211000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 23.55% to $211000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $211000.0, a 23.55% decrease, with the full-year FY2024 number at $216000.0, down 29.64% from a year prior.
  • Other Non-Current Assets was $211000.0 for Q3 2025 at Vivos Therapeutics, down from $255000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $374648.0 in Q2 2021 to a low of $211000.0 in Q3 2025.
  • A 5-year average of $311431.3 and a median of $308000.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: grew 15.21% in 2021, then tumbled 30.19% in 2025.
  • Vivos Therapeutics' Other Non-Current Assets stood at $356000.0 in 2021, then grew by 5.06% to $374000.0 in 2022, then fell by 17.91% to $307000.0 in 2023, then dropped by 29.64% to $216000.0 in 2024, then dropped by 2.31% to $211000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Non-Current Assets are $211000.0 (Q3 2025), $255000.0 (Q2 2025), and $215000.0 (Q1 2025).